RAN
0.005
66.7%
MGX
0.345
-26.6%
EVG
0.038
52%
EG1
0.052
-20%
TAS
0.033
43.5%
TMX
0.004
-20%
C7A
0.004
33.3%
YUG
0.044
-18.5%
HWK
0.04
33.3%
ALM
0.009
-18.2%
PKY
0.02
33.3%
FCT
0.014
-17.6%
WSR
0.008
33.3%
CR9
0.005
-16.7%
UNT
0.013
30%
OVT
0.005
-16.7%
ELT
0.36
28.6%
THR
0.015
-16.7%
TAT
0.054
28.6%
VAR
0.005
-16.7%
SKK
0.065
27.5%
IFG
0.011
-15.4%
AAJ
0.029
26.1%
ATR
0.915
-15.3%
OEL
0.005
25%
GTE
0.017
-15%
PIL
0.005
25%
RAU
0.255
-15%
PFT
0.037
23.3%
MDR
0.023
-14.8%
VHL
0.032
23.1%
CPM
0.053
-14.5%
VBS
0.17
21.4%
EXT
0.012
-14.3%
EMH
0.265
20.5%
GED
0.062
-13.9%
RBX
0.055
19.6%
YAR
0.013
-13.3%
LMG
0.043
19.4%
CR1
0.2
-13%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

NEU Phase 2 trial shows significant improvements

Neuren Pharmaceuticals (ASX:NEU) announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome. Significant improvement was observed by both clinicians and caregivers from treatment | ASX announcement: https://www.neurenpharma.com/pdf/f9ca13b8-b75f-4ff5-a5b7-1dcb75d547d6/P2-trial-shows-significant-improvements-in-PhelanMcDermid.pdf #shorts